Skip to main content
SpringerLink
Log in

Influenza virus RIV4 vaccine (Flublok Quadrivalent): VAERS reports

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Woo EJ, et al. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system. Vaccine : 4 Mar 2021. Available from: URL: http://doi.org/10.1016/j.vaccine.2021.02.052

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Influenza virus RIV4 vaccine (Flublok Quadrivalent): VAERS reports. Reactions Weekly 1847, 8 (2021). https://doi.org/10.1007/s40278-021-92565-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-92565-3

Search

Navigation